Ophthalmology Times Newsletter

To view this email as a web page, click here.

Gene therapy for LHON: Deciphering phase III data

Phase III studies of a gene therapy for Leber Hereditary Optic Neuropathy have generated some unexpected positive findings. There is biologic plausibility to explain the data.

Read on

Budding technology could be an OCT analysis game-changer

Tools for higher-order OCT assessment enable evaluation of features of interest, such as targeted retinal layers or fluid compartments, and may allow for unique characterization of disease phenotypes and treatment response.

Find out

Weigh risk, benefits of cataract surgery for your patients

Doug Katsev, MD, takes a look at two key factors for patients suffering from vision loss who are also considering undergoing cataract surgery, including the association with age-related macular degeneration (AMD).

Learn more

Teleglaucoma lets patients be more engaged in care

Safety key for intracamerally injected mydriatic agents in cataract surgery

Understand the expanding role of IPL in dry eye disease

These 3 things are part of a cataract surgeon’s signature

10 effective habits of a cataract surgeon

Quieting the neuropathic components of ocular pain

Pearls to manage cataract surgery on hypotonous eyes

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.